GO
Loading...

Amgen Inc

More

  • Rally or not, these industries are in a correction Wednesday, 21 May 2014 | 12:47 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks may be rallying Wednesday, but there are still plenty of industries that have lost substantial ground.

  • *Sanofi has restructured R&D, has strong pipeline-Zerhouni. PARIS, May 15- France's Sanofi has strengthened its drug pipeline and has enough future blockbusters lined up for it to steer clear of the M&A frenzy "overheating" the industry, the drugmaker's R&D chief told Reuters.

  • *$106 bln Pfizer bid stirs up political storm on job fears. LONDON, May 11- How British is AstraZeneca? With a French chief executive, Swedish chairman, 40 percent of its sales in the United States and 87 percent of its staff overseas, the answer is not simple.

  • Lightning Round: Noodles & Co., TriNet & More Thursday, 8 May 2014 | 6:44 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • LONDON, April 29- U.S. drugmaker Pfizer will need to raise its bid for AstraZeneca to around $105- 110 billion and increase the proportion of cash in the offer to win its British rival, investors believe.

  • US STOCKS-Wall St snaps six-day run; Apple to split stock Wednesday, 23 Apr 2014 | 5:19 PM ET

    *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks dipped on Wednesday to snap a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.

  • Stocks mostly fell Wednesday after earnings from Boeing and AT&T.

  • *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks dipped on Wednesday to snap a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.

  • *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks declined on Wednesday after a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.

  • *AT&T falls after results, but Boeing rallies. *Amgen drags biotech lower, but Gilead gains. NEW YORK, April 23- U.S. stocks edged lower on Wednesday as weakness in AT&T and biotech names inspired investors to take profits following six straight days of gains, though a rally in Boeing limited losses.

  • US STOCKS-Wall St edges lower following six-day S&P rally Wednesday, 23 Apr 2014 | 10:17 AM ET

    *Boeing rallies after results, outlook; AT&T drops. NEW YORK, April 23- U.S. stocks edged lower on Wednesday as strong results from Boeing failed to inspire investors to keep pushing equities higher following six straight days of gains.

  • Early movers: PG, BA, T, DAL, YUM, TM, SKX & more Wednesday, 23 Apr 2014 | 7:49 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as sales of several key products fell short of Wall Street estimates, with its big-selling rheumatoid arthritis drug Enbrel particularly hard hit by inventory stocking by wholesalers late last year.

  • After-hours buzz: AT&T, Amgen, VMware & More Tuesday, 22 Apr 2014 | 5:00 PM ET

    Headlines after the bell: T, AMGN, VMW

  • April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as results were hurt by acquisition-related costs as well as sales of several key products that fell short of Wall Street estimates.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Value stocks to stay in vogue, as momentum fades Monday, 21 Apr 2014 | 5:41 PM ET

    With the wipeout in growth stocks, many investors turned their attention to big-cap and value names, and the trend is expected to continue.

  • Can Gilead’s Sovaldi rescue biotech? Monday, 21 Apr 2014 | 12:20 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.

  • AstraZeneca cancer pipeline seen as draw for Pfizer Monday, 21 Apr 2014 | 6:55 AM ET

    LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.